A Phase II Study of Carfilzomib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

NCT02042950 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

6

Enrollment

OTHER

Sponsor class

Stopped Terminated due to poor accrual

Conditions

Lymphoma

Interventions

DRUG: Carfilzomib

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]